TrialChinese medical journal2018

Three-year Follow-up on the Safety and Effectiveness of Rituximab Plus Chemotherapy as First-Line Treatment of Diffuse Large B-Cell Lymphoma and Follicular Lymphoma in Real-World Clinical Settings in China: A Prospective, Multicenter, Noninterventional Study.

Jian-Qiu Wu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.